INC Research (NASDAQ:INCR) received a $41.00 target price from investment analysts at Mizuho in a research note issued to investors on Friday, December 1st, Marketbeat reports. The firm currently has a “neutral” rating on the stock. Mizuho’s target price would indicate a potential downside of 5.96% from the company’s previous close.
Several other research analysts also recently commented on the stock. TheStreet upgraded shares of INC Research from a “c” rating to a “b-” rating in a report on Monday, November 6th. Goldman Sachs Group reiterated a “buy” rating and issued a $65.00 target price on shares of INC Research in a report on Monday, August 7th. Credit Suisse Group began coverage on shares of INC Research in a report on Wednesday, October 11th. They issued an “outperform” rating and a $68.00 target price on the stock. Jefferies Group upgraded shares of INC Research from a “hold” rating to a “buy” rating and lifted their target price for the stock from $62.50 to $69.00 in a report on Monday, October 9th. Finally, Robert W. Baird reiterated a “buy” rating and issued a $67.00 target price on shares of INC Research in a report on Monday, October 9th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and five have given a buy rating to the company. INC Research presently has a consensus rating of “Hold” and a consensus price target of $50.56.
INC Research (NASDAQ:INCR) traded down $0.10 during trading on Friday, hitting $43.60. 1,093,076 shares of the stock were exchanged, compared to its average volume of 1,420,862. The company has a market cap of $4,559.88, a P/E ratio of -75.17, a P/E/G ratio of 1.38 and a beta of 1.08. The company has a quick ratio of 1.27, a current ratio of 1.27 and a debt-to-equity ratio of 0.99. INC Research has a fifty-two week low of $33.60 and a fifty-two week high of $61.10.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of INC Research by 14.8% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,765 shares of the company’s stock worth $103,000 after purchasing an additional 228 shares during the period. Pacad Investment Ltd. bought a new position in shares of INC Research during the 2nd quarter worth about $123,000. Riverhead Capital Management LLC bought a new position in shares of INC Research during the 2nd quarter worth about $128,000. Victory Capital Management Inc. increased its holdings in shares of INC Research by 17.6% during the 2nd quarter. Victory Capital Management Inc. now owns 2,377 shares of the company’s stock worth $139,000 after purchasing an additional 356 shares during the period. Finally, Personal Capital Advisors Corp bought a new position in shares of INC Research during the 3rd quarter worth about $234,000. Hedge funds and other institutional investors own 99.50% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was originally published by American Banking and Market News and is the sole property of of American Banking and Market News. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/12/30/mizuho-analysts-give-inc-research-incr-a-41-00-price-target.html.
INC Research Company Profile
INC Research Holdings, Inc is a global contract research organization (CRO). The Company focuses on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services.